Technologies for medical device usage tracking and analysis

USPTO granted patent US12597510B2 to DePuy Synthes Products, Inc. on April 7, 2026, covering a system for medical device usage monitoring using capture devices, base stations with machine learning models, and analytics servers to track and analyze medical device usage in operating rooms. The patent includes 11 claims related to computer vision-based medical device recognition and usage analytics.

Systems and Methods for Medical Device Task Generation and Management

USPTO granted patent US12597509B2 to Sage Products, LLC on April 7, 2026. The patent covers a method for generating and managing medical device tasks using patient data and device data, with tasks including due dates, due times, and completion status indicators. The grant establishes enforceable intellectual property rights for the assignee.

Lab Automation Data Sharing System and Methods

USPTO granted patent US12596131B2 to Gen-Probe Incorporated on April 7, 2026, covering a method for sharing system information data between networked diagnostic instruments used for performing assays. The patent contains 7 claims and was originally filed December 1, 2020, under application number 17781249.

Devices, Systems, and Methods for Providing Remote Support to a User of Care Components

The USPTO granted Patent US12594205B2 to Liko Research & Development AB covering assistive control devices and audiovisual communications systems for providing remote assistance to users of care components. The patent includes 20 claims and spans CPC classifications in health informatics (G16H). The invention enables remote operation of subject care components through audiovisual communications integrated with assistive control devices.

Artificial intelligence based technologies for improving patient appointment scheduling and inventory management

USPTO granted US Patent 12,597,511 B2 to CDW LLC covering AI-based technologies for patient appointment scheduling and inventory management. The patented system uses natural language processing to interpret verbal patient responses and queries a scheduling database to match appointments based on distance, date, service, and inventory thresholds. The patent includes 15 claims and names inventors Casey Bleeker and Nathan A. Cartwright.

Methods and Devices for Secure Communication with and Operation of an Implant

USPTO granted patent US12598458B2 to Peter Forsell covering methods and devices for secure communication with and operation of an implantable medical device. The patent includes 20 claims directed to an apparatus for powering an implant using an implantable energy source with an energy provider configured to store and deliver burst energy during startup. CPC classifications H04W 12/033 (secure data handling) and G16H 40/67 (implantable medical device management) indicate applications in remote monitoring and secure patient data transmission.

Health management and guidance instruction issuance assistance

The USPTO granted patent US12597515B2 to Koga Software Co., Ltd. on April 7, 2026, covering a health management system that facilitates collaboration between patients, exercise/nutrition specialists, and doctors through networked servers. The system enables automated creation and manual correction of guidance instructions for exercise and nutrition prescriptions.

Benzalkonium Chloride for Treating COVID-19 and Conjunctivitis

USPTO granted patent US12594251B2 to Bausch + Lomb Ireland Limited on April 7, 2026, covering methods of treating COVID-19 (including ocular manifestations) and conjunctivitis using benzalkonium chloride, as well as methods for reducing COVID-19 transmission using the compound. The patent, with inventors Patrick McCormick and Kimberly Millard, contains 40 claims and is classified under CPC codes A61K 31/14, A61P 27/02, and A61P 31/14.

Small molecule compounds for treating lung epithelial and vascular endothelial cell injury

USPTO granted patent US12594282B2 to Guangzhou Cellprotek Pharmaceutical Co., Ltd. on April 7, 2026. The patent covers the use of 5α-androst-3β,5,6β-triol and analogues for treating pulmonary diseases mediated by lung epithelial cell injury and/or vascular endothelial cell injury. The compounds inhibit PFKFB3 expression and reduce vascular endothelial and alveolar epithelial cell injury.

SCYNEXIS patent for triterpenoid antifungals treating Pneumocystis pneumonia

The USPTO issued patent US12594266B2 to SCYNEXIS, INC. on April 7, 2026, covering eufumafungin derivative triterpenoid antifungal compounds and their use in treating or preventing Pneumocystis pneumonia (PCP). The patent includes 16 claims encompassing the compound structures, pharmaceutical compositions, and methods of treatment.